1	Mujer	mujer	NCFS000	C0043210#C0015780#C0086418	persona#hallazgo#estructura_corporal#organismo_vivo	0-5	485_QUEST_clinical_caseMIR	SENT1	-	-
2	de	de	SPS00	C0332285	atributo	6-8	485_QUEST_clinical_caseMIR	SENT1	-	-
3	40	40		-	-	9-11	485_QUEST_clinical_caseMIR	SENT1	-	-
4	años	año	NCMP000	C0439234	calificador	12-16	485_QUEST_clinical_caseMIR	SENT1	-	-
5	que	que	PR0CN000	-	-	17-20	485_QUEST_clinical_caseMIR	SENT1	-	-
6	consulta	consultar	VMM02S0	C1704447_1	calificador_1	21-29	485_QUEST_clinical_caseMIR	SENT1	-	-
7	por	por	SPS00	C1704447_2	calificador_2	30-33	485_QUEST_clinical_caseMIR	SENT1	-	-
8	anemia	anemia	NCFS000	C0002871#C0221395#C1510654	trastorno	34-40	485_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
9	.	.	Fp	-	-	40-41	485_QUEST_clinical_caseMIR	SENT1	-	-

1	En	en	SPS00	C1720294#C0332285	calificador#atributo	42-44	485_QUEST_clinical_caseMIR	SENT2	-	-
2	la	el	DA0FS0	-	-	45-47	485_QUEST_clinical_caseMIR	SENT2	-	-
3	analítica	analítica	NCFS000	-	-	48-57	485_QUEST_clinical_caseMIR	SENT2	-	-
4	destaca	destacar	VMIP3S0	-	-	58-65	485_QUEST_clinical_caseMIR	SENT2	-	-
5	Hb	hb	NC00YL0	-	-	66-68	485_QUEST_clinical_caseMIR	SENT2	-	-
6	10,5	10.5	Z	-	-	69-73	485_QUEST_clinical_caseMIR	SENT2	-	-
7	g	g	NCMN000	-	-	74-75	485_QUEST_clinical_caseMIR	SENT2	-	-
8	/	/	Fh	-	-	75-76	485_QUEST_clinical_caseMIR	SENT2	-	-
9	dL	decilitro	NCMN000	C0439241	calificador	76-78	485_QUEST_clinical_caseMIR	SENT2	-	-
10	,	,	Fc	-	-	78-79	485_QUEST_clinical_caseMIR	SENT2	-	-
11	ferropenia	ferropenia	NC00KE0	-	-	80-90	485_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
12	,	,	Fc	-	-	90-91	485_QUEST_clinical_caseMIR	SENT2	-	-
13	macrocitosis	macrocitosis	NCFN000	C2004480	anomalía_morfológica	92-104	485_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
14	e	y	CC	C1706368	calificador	105-106	485_QUEST_clinical_caseMIR	SENT2	-	-
15	hipergastrinemia	hipergastrinemia	NC00SC0	C0232567	hallazgo	107-123	485_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
16	.	.	Fp	-	-	123-124	485_QUEST_clinical_caseMIR	SENT2	-	-

1	Tiene	tener	VMIP3S0	-	-	125-130	485_QUEST_clinical_caseMIR	SENT3	-	-
2	antecedentes	antecedente	NCMP000	-	-	131-143	485_QUEST_clinical_caseMIR	SENT3	-	-
3	artropatía	artropatía	NCFS000	C0022408	trastorno	144-154	485_QUEST_clinical_caseMIR	SENT3	B-Grp_Enfermedad	-
4	lúpica	lúpica	AQ0FS00	-	-	155-161	485_QUEST_clinical_caseMIR	SENT3	B-Calificador	-
5	y	y	CC	C1706368	calificador	162-163	485_QUEST_clinical_caseMIR	SENT3	-	-
6	enfermedad	enfermedad	NCFS000	C0012634#C0039082	trastorno	164-174	485_QUEST_clinical_caseMIR	SENT3	B-Grp_Enfermedad	-
7	de	de	SPS00	C0332285	atributo	175-177	485_QUEST_clinical_caseMIR	SENT3	I-Grp_Enfermedad	-
8	Graves	grave	AQ0CP0	C0439808#C0205082	calificador	178-184	485_QUEST_clinical_caseMIR	SENT3	I-Grp_Enfermedad	-
9	Basedow	Basedow		-	-	185-192	485_QUEST_clinical_caseMIR	SENT3	I-Grp_Enfermedad	-
10	.	.	Fp	-	-	192-193	485_QUEST_clinical_caseMIR	SENT3	-	-

1	Está	estar	VAM02S0	-	-	194-198	485_QUEST_clinical_caseMIR	SENT4	-	-
2	en	en	SPS00	C1720294#C0332285	calificador#atributo	199-201	485_QUEST_clinical_caseMIR	SENT4	-	-
3	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	202-213	485_QUEST_clinical_caseMIR	SENT4	-	-
4	con	con	SPS00	C0332287	atributo	214-217	485_QUEST_clinical_caseMIR	SENT4	-	-
5	prednisona	prednisona	NCFS000	C0032952	sustancia	218-228	485_QUEST_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
6	15	15	Z	-	-	229-231	485_QUEST_clinical_caseMIR	SENT4	-	-
7	mg	mg	NCMN000	-	-	232-234	485_QUEST_clinical_caseMIR	SENT4	-	-
8	/	/	Fh	-	-	234-235	485_QUEST_clinical_caseMIR	SENT4	-	-
9	d	d	NCFS000	-	-	235-236	485_QUEST_clinical_caseMIR	SENT4	-	-
10	,	,	Fc	-	-	236-237	485_QUEST_clinical_caseMIR	SENT4	-	-
11	colchicina	colchicina	NC00SC0	C0009262	producto#sustancia	238-248	485_QUEST_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
12	0,5	0,5		-	-	249-252	485_QUEST_clinical_caseMIR	SENT4	-	-
13	mg	miligramo	NCMN000	C0439210	calificador	253-255	485_QUEST_clinical_caseMIR	SENT4	-	-
14	cada	cada	DI0CS0	C1457900	calificador	256-260	485_QUEST_clinical_caseMIR	SENT4	-	-
15	12	12	Z	-	-	261-263	485_QUEST_clinical_caseMIR	SENT4	-	-
16	h	h	NCMN000	C0439227	calificador	264-265	485_QUEST_clinical_caseMIR	SENT4	-	-
17	y	y	CC	C1706368	calificador	266-267	485_QUEST_clinical_caseMIR	SENT4	-	-
18	metimazol	metimazol	NC00SC0	C0025644	sustancia#producto	268-277	485_QUEST_clinical_caseMIR	SENT4	B-Grp_Medicamento	-
19	10	10	Z	-	-	278-280	485_QUEST_clinical_caseMIR	SENT4	-	-
20	mg	mg	NCMN000	-	-	281-283	485_QUEST_clinical_caseMIR	SENT4	-	-
21	/	/	Fh	-	-	283-284	485_QUEST_clinical_caseMIR	SENT4	-	-
22	d.	d.	NCFS000	-	-	284-286	485_QUEST_clinical_caseMIR	SENT4	-	-
23	Cuál	cuál	PT0CS000	-	-	287-291	485_QUEST_clinical_caseMIR	SENT4	-	-
24	considera	considerar	VMIP3S0	-	-	292-301	485_QUEST_clinical_caseMIR	SENT4	-	-
25	la	el	DA0FS0	-	-	302-304	485_QUEST_clinical_caseMIR	SENT4	-	-
26	causa	causa	NCFS000	-	-	305-310	485_QUEST_clinical_caseMIR	SENT4	-	-
27	más	más	RG	C0205172	calificador	311-314	485_QUEST_clinical_caseMIR	SENT4	-	-
28	probable	probable	AQ0CS0	C0332148	calificador	315-323	485_QUEST_clinical_caseMIR	SENT4	-	-
29	de	de	SPS00	C0332285	atributo	324-326	485_QUEST_clinical_caseMIR	SENT4	-	-
30	la	el	DA0FS0	-	-	327-329	485_QUEST_clinical_caseMIR	SENT4	-	-
31	anemia	anemia	NCFS000	C0002871#C0221395#C1510654	trastorno	330-336	485_QUEST_clinical_caseMIR	SENT4	B-Grp_Enfermedad	Especulacion
32	.	.	Fp	-	-	336-337	485_QUEST_clinical_caseMIR	SENT4	-	-

